Amgen (AMGN): Phase 3 romosozumab Answers Some Questions - BMO

September 20, 2016 9:16 AM EDT Send to a Friend
BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating Amgen (NASDAQ: AMGN) after Amgen released additional results from its ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login